PJSC Kraspharma has registered a new carbapenem antibiotic — Dorifarm.
25.02.2025
PJSC Kraspharma has registered a new carbapenem antibiotic — Dorifarm.
A new product in PJSC Kraspharma’s portfolio of carbapenem antibiotics is Dorifarm (INN: doripenem).
Dorifarm features a broad spectrum of activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. Its efficacy is largely due to its stability against hydrolysis by most β-lactamases. In vitro studies show that doripenem is 2 to 4 times more active than imipenem and meropenem against Pseudomonas aeruginosa and demonstrates a low potential for inducing resistance among Gram-negative organisms.
Like other carbapenems, doripenem has a favorable safety profile, supported by its pharmacokinetic characteristics:
Key indications for Dorifarm include:
View in catalog
Dorifarm features a broad spectrum of activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. Its efficacy is largely due to its stability against hydrolysis by most β-lactamases. In vitro studies show that doripenem is 2 to 4 times more active than imipenem and meropenem against Pseudomonas aeruginosa and demonstrates a low potential for inducing resistance among Gram-negative organisms.
Like other carbapenems, doripenem has a favorable safety profile, supported by its pharmacokinetic characteristics:
- Low affinity for GABA receptors in the central nervous system, resulting in a low risk of seizure induction;
- Does not inhibit major cytochrome P450 isoenzymes, which minimizes the risk of significant drug interactions.
Key indications for Dorifarm include:
- Hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia (VAP);
- Complicated intra-abdominal infections;
- Urinary tract infections, including cases accompanied by bacteremia.
View in catalog
